ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Ovid Therapeutics, Inc. ?
1
Poor long term growth as Operating profit has grown by an annual rate 8.14% of over the last 5 years
2
The company has declared positive results for the last 2 consecutive quarters
- NET SALES(HY) At USD 0.72 MM has Grown at 248.54%
- OPERATING CASH FLOW(Y) Highest at USD -41.95 MM
- NET PROFIT(HY) Higher at USD 13.66 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 700.00%, its profits have risen by 114% ; the PEG ratio of the company is 0.7
4
High Institutional Holdings at 77.9%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Market Beating Performance
- The stock has generated a return of 700.00% in the last 1 year, much higher than market (S&P 500) returns of 22.24%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Ovid Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Ovid Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Ovid Therapeutics, Inc.
700.0%
-0.22
113.31%
S&P 500
22.24%
1.67
13.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-10.49%
EBIT Growth (5y)
8.14%
EBIT to Interest (avg)
-27.73
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.70
Sales to Capital Employed (avg)
0.04
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
77.90%
ROCE (avg)
0
ROE (avg)
12.05%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
83
Industry P/E
Price to Book Value
2.32
EV to EBIT
-5.54
EV to EBITDA
-5.58
EV to Capital Employed
3.76
EV to Sales
32.42
PEG Ratio
0.73
Dividend Yield
NA
ROCE (Latest)
-67.95%
ROE (Latest)
2.79%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend25What is working for the Company
NET SALES(HY)
At USD 0.72 MM has Grown at 248.54%
OPERATING CASH FLOW(Y)
Highest at USD -41.95 MM
NET PROFIT(HY)
Higher at USD 13.66 MM
ROCE(HY)
Highest at -18.77%
RAW MATERIAL COST(Y)
Fallen by -88.49% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -71.85 %
-9What is not working for the Company
OPERATING PROFIT(Q)
Lowest at USD -17.81 MM
PRE-TAX PROFIT(Q)
Lowest at USD -16.99 MM
NET PROFIT(Q)
Lowest at USD -16.99 MM
Here's what is working for Ovid Therapeutics, Inc.
Net Sales
At USD 0.72 MM has Grown at 248.54%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD -41.95 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Debt-Equity Ratio
Lowest at -71.85 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by -88.49% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Ovid Therapeutics, Inc.
Pre-Tax Profit
At USD -16.99 MM has Fallen at -1,967.33%
over average net sales of the previous four periods of USD 0.91 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -16.99 MM has Fallen at -1,967.33%
over average net sales of the previous four periods of USD 0.91 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Operating Profit
Lowest at USD -17.81 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (USD MM)
Pre-Tax Profit
Lowest at USD -16.99 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
Lowest at USD -16.99 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
